Article source：Kexing Biopharm
Sep 04,2025
View：
226 Kexing Biopharm is rapidly establishing itself as a global, comprehensive, and innovation-driven pharmaceutical enterprise, steadily moving toward the ranks of multinational pharmaceutical companies. With an unwavering commitment to scientific research, international collaboration, and market expansion, Kexing Biopharm has successfully positioned itself as one of China’s Top 20 Biopharmaceutical Enterprises. This recognition is a testament to its accelerating R&D capabilities, growing global footprint, and its long-term strategy of platform-driven innovation.
This article will explore the key factors behind Kexing’s rise, focusing on industry recognition, research acceleration, market expansion, and global collaboration. It also highlights how Kexing’s innovation strategy is transforming the company into a competitive multinational biopharma leader.
The Chinese biopharmaceutical sector is one of the fastest-growing industries globally, with fierce competition and increasing innovation requirements. Being recognized as one of China’s Top 20 Biopharmaceutical Enterprises places Kexing Biopharm in a distinguished group of companies leading the transformation of China’s healthcare and biotechnology landscape.
Kexing Biopharm has consistently increased investment in R&D, with year-on-year growth exceeding 50% in recent cycles. This strategic investment fuels the advancement of its diverse product pipeline, covering areas such as oncology, immunology, virology, and metabolic diseases.
Kexing’s R&D is structured around its “3KX” innovation platforms:
KX-BODY Platform: A cutting-edge antibody technology platform, including FIT-BODY for monoclonal discovery, FIGHT-BODY for bispecifics, and FLEX-BODY for multifunctional fusion proteins.
KX-FUSION Platform: Focused on fusion protein therapeutics with enhanced stability and efficacy.
KX-Exosome Platform: Exploring novel exosome-based therapies with potential in regenerative medicine and targeted delivery.
By leveraging these platforms, Kexing maximizes innovation efficiency while ensuring scalability and adaptability for global markets.
GB05: An inhalable interferon α1b for RSV lower respiratory infections in children, already receiving U.S. FDA IND approval.
GB18: A nanobody targeting GDF-15 for cancer cachexia, progressing toward clinical stages.
Biologics Portfolio: Includes recombinant EPO, G-CSF, adalimumab, bevacizumab, and more, expanding both in China and globally.
Kexing Biopharm maintains a robust domestic distribution network covering:
8,000+ hospitals
8,900+ third-end medical institutions
4,000+ retail pharmacies
This extensive reach ensures that Kexing’s products are accessible to millions of patients in China, reinforcing its market leadership.
Kexing’s international strategy has extended its presence to over 40 countries worldwide. With a growing network of partnerships and licensing agreements, the company is actively expanding into regulated markets, including the United States, Europe, and Asia-Pacific.
This global expansion reflects Kexing’s transition from a regional player to a truly international biopharma company.
Kexing Biopharm recognizes that collaboration is central to its internationalization strategy. By partnering with global leaders such as IQVIA, the company is able to:
Accelerate clinical trial execution and regulatory navigation.
Access advanced data analytics to optimize R&D efficiency.
Strengthen commercialization strategies for overseas launches.
These collaborations not only enhance Kexing’s global competitiveness but also build a foundation for long-term multinational operations.
As part of its global mission, Kexing integrates ESG principles into its operations. The company focuses on:
Sustainability: Environmentally responsible production practices.
Community Support: Public health initiatives and community engagement.
Global Health: Commitment to accessible, high-quality medicines worldwide.
Kexing also adheres strictly to GMP standards and pharmacovigilance systems, ensuring safety, quality, and compliance across all markets.
Kexing’s rise into China’s Top 20 Biopharmaceutical Enterprises is driven by a combination of unique strengths:
Diversified Product Pipeline: Covering biologics, recombinant proteins, antibodies, and microecological preparations.
Innovation Platforms: Proprietary 3KX platforms providing scalability and adaptability.
Domestic Market Penetration: Extensive distribution network ensuring national coverage.
International Expansion: Proactive strategy for entering regulated global markets.
Sustainability and Quality: Strong ESG practices and robust quality systems.
These factors position Kexing as a company with both short-term market impact and long-term global potential.
Kexing Biopharm’s recognition as one of China’s Top 20 Biopharmaceutical Enterprises underscores its remarkable progress in accelerated R&D, market expansion, and global collaboration. By combining platform-driven innovation with a strong domestic foundation and international ambitions, the company is evolving into a global, comprehensive, innovation-oriented biopharma enterprise.
BACK TO LIST
Sep 06,2023
